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Abstract
Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme in the
pentose phosphate pathway (PPP) and plays an essential role in the
oxidative stress response by producing NADPH, the main intracellular
reductant. G6PD deficiency is the most common human enzyme
defect, affecting more than 400 million people worldwide. Here, we
show that G6PD is negatively regulated by acetylation on lysine 403
(K403), an evolutionarily conserved residue. The K403 acetylated
G6PD is incapable of forming active dimers and displays a complete
loss of activity. Knockdown of G6PD sensitizes cells to oxidative
stress, and re-expression of wild-type G6PD, but not the K403 acety-
lation mimetic mutant, rescues cells from oxidative injury. Moreover,
we show that cells sense extracellular oxidative stimuli to decrease
G6PD acetylation in a SIRT2-dependent manner. The SIRT2-mediated
deacetylation and activation of G6PD stimulates PPP to supply cyto-
solic NADPH to counteract oxidative damage and protect mouse
erythrocytes. We also identified KAT9/ELP3 as a potential acetyl-
transferase of G6PD. Our study uncovers a previously unknown
mechanism by which acetylation negatively regulates G6PD activity
to maintain cellular NADPH homeostasis during oxidative stress.
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Introduction
Nicotinamide adenine dinucleotide phosphate (NADPH) is a func-
tionally important metabolite that is commonly used for reductive
biosynthesis and maintenance of cellular redox potential. It is a
required cofactor in reductive biosynthesis of fatty acids, isopre-
noids, and aromatic amino acids (Turner & Turner, 1980; Graeve
et al, 1994; Hauschild & von Schaewen, 2003). NADPH is also used
to keep glutathione in its reduced form. Reduced glutathione (GSH)
acts as a scavenger for dangerous oxidative metabolites in the cell,
and it converts harmful hydrogen peroxide to water with the help of
glutathione peroxidase (GSHPx) (Margis et al, 2008). Perturbed
NADPH production increases sensitivity to reactive oxygen species
(ROS) and provokes apoptosis (Kim et al, 2007). Despite the func-
tional importance of NADPH, mechanisms of maintaining cellular
NADPH homeostasis are not fully understood.
Numerous pathways are known to maintain cellular NADPH
levels. The major NADPH-producing enzymes in the cell are
glucose-6-phosphate dehydrogenase (G6PD) and 6-phospho-
gluconate dehydrogenase (6PGD) in the pentose phosphate
pathway (PPP), malic enzyme (ME) in the pyruvate cycling path-
way, and isocitrate dehydrogenase (IDH) in the tricarboxylic acid
(TCA) cycle (Salati & Amir-Ahmady, 2001). Activity of IDH1, ME1,
and 6PGD remains unchanged during oxidative stress, while G6PD
is the only NADPH-producing enzyme that is activated (Filosa et al,
2003). G6PD catalyzes the oxidation of glucose-6-phosphate to
6-phosphogluconate and concomitantly reduces NADP+ to NADPH,
which is the rate-limiting and primary control step of the NADPH-
generating portion in the PPP. Thus, G6PD acts as a guardian
of cellular redox potential during oxidative stress (Filosa et al,
2003).
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G6PD is highly conserved from yeast to mammalian species
(Kletzien et al, 1994; Notaro et al, 2000). Yeast carries one G6PD
gene, Zwf1, which when deleted causes phenotypes indicative of
hypersensitivity to oxidative stress, including aerobic methionine
auxotrophy and sensitivity to hydrogen peroxide (Juhnke et al,
1996; Lee et al, 1999; Blank et al, 2005). The critical function of
G6PD in oxidative stress response is also conserved in mammals.
Mouse embryonic stem cells with G6PD deletion display an approxi-
mately 50% reduction in the [NADPH]/[NADP+] ratio and are
extremely sensitive to the lethal effects of external chemical
oxidants (Pandolfi et al, 1995; Filosa et al, 2003). Furthermore,
human G6PD deficiency is a common genetic abnormality found in
5–10% of the global population (Cappellini & Fiorelli, 2008). While
the polymorphic mutations in G6PD affect amino acid residues
throughout the enzyme and decrease the stability of the enzyme in
the red blood cell, the severe mutations mostly affect residues at the
dimer interface or those that interact with a structural NADP+ mole-
cule that stabilizes the enzyme (Mason et al, 2007). The distinctive
phenotype of patients with G6PD deficiency is chronic and drug- or
food-induced hemolytic anemia, which is attributed to the inability
to produce NADPH and withstand harmful oxidants in erythrocyte
cells where other NADPH-producing enzymes are lacking (Vulliamy
et al, 1993). Together, these findings further support the notion that
G6PD is of central importance for NADPH homeostasis and redox
regulation.
We and others have previously discovered that lysine acetylation
is an evolutionarily conserved post-translational modification in the
regulation of a wide range of cellular processes, particularly in
nuclear transcription and cytoplasmic metabolism (Kim et al, 2006;
Choudhary et al, 2009; Zhao et al, 2010). The acetylation state of a
given protein results from the balanced action of lysine acetyl-
transferases (KATs) and deacetylases (KDACs), enzymes that cata-
lyze the addition and removal, respectively, of an acetyl group from
a lysine residue. In particular, KDACs including classical HDACs
(histone deacetylases) and sirtuins (SIRTs) have received more and
more attention not only for their physiological roles, but also for
their involvement in disease states and, consequently, for being a
therapeutic target (Haberland et al, 2009). Several recent acetylome
proteomic studies have identified more than 4,500 acetylated
proteins (Kim et al, 2006; Choudhary et al, 2009; Zhao et al, 2010;
Lundby et al, 2012). Among these identified acetylated proteins is
G6PD, implicating a novel regulatory mechanism of G6PD at the
post-translational level. This study is directed toward identifying
potential KAT and KDAC enzymes of G6PD and understanding how
acetylation regulates G6PD activity to maintain cellular NADPH
homeostasis and redox potential during oxidative stress.
Results
Lysine 403 is an important regulatory acetylation site in G6PD
In a recent proteomic study (Choudhary et al, 2009), G6PD was
identified to be acetylated on 7 lysine residues, including lysine 89
(K89), lysine 171 (K171), lysine 386 (K386), lysine 403 (K403),
lysine 432 (K432), lysine 497 (K497), and lysine 514 (K514) (Supple-
mentary Fig S1). Western blotting with a pan-anti-acetyllysine anti-
body demonstrated that G6PD was indeed acetylated and its
acetylation was significantly elevated (up to ~2.5-fold) in HEK293T
cells after treatment with nicotinamide (NAM), an inhibitor of the
SIRT family deacetylases (Bitterman et al, 2002; Avalos et al, 2005;
Smith et al, 2008) (Fig 1A). The effect of NAM on increasing G6PD
acetylation was found to be in a dose-dependent manner, while
G6PD specific activity was decreased by as much as 40% after NAM
treatment (Fig 1A). Treatment with trichostatin A (TSA), an inhibi-
tor of histone deacetylase HDAC (Furumai et al, 2001), did not
affect G6PD acetylation and activity (Supplementary Fig S2), and
additional treatment with TSA did not further change either G6PD
acetylation or its enzyme activity in cells co-treated with NAM
(Fig 1A). When purified G6PD protein was incubated in vitro with
bacterial deacetylase CobB (Zhao et al, 2004) in the presence of
NAD+, G6PD acetylation was decreased by twofold and concomi-
tantly its enzymatic activity was increased by as much as twofold
(Fig 1B). These data suggest that acetylation negatively regulates
G6PD activity.
Because G6PD is a highly conserved protein (Kletzien et al,
1994), we speculated that important regulatory sites targeted by
acetylation might be also conserved. Sequence alignments from
diverse species revealed that five of the acetylated lysines (K89,
K386, K432, K497, and K514) are not conserved, while two lysines
(K171 and K403) are invariant (Supplementary Fig S1). To deter-
mine which lysine residue(s) plays a major role in the regulation of
G6PD, we mutated each of the 7 putative acetylation sites to argi-
nine (R) or glutamine (Q) and assayed their activity individually.
The K to R mutation retains a positive charge and is often used as a
deacetylated mimetic, whereas the K to Q mutation abolishes the
positive charge and may act as a surrogate of acetylation (Megee
et al, 1990). By continuously monitoring the generation of NADPH
(Tian et al, 1998), we found that substitutions at K89, K432, K497,
and K514 did not significantly affect G6PD activity as compared
with wild-type G6PD (Fig 1C and D). Mutation of K171 to either
arginine or glutamine led to a complete loss in G6PD catalytic activ-
ity (Fig 1C and D). Mutation of either K386 or K403 to glutamine,
but not to arginine, resulted in a significant reduction in G6PD activ-
ity (Fig 1C and D). Moreover, the K386R mutant responded
normally to NAM treatment regarding G6PD acetylation and enzyme
activity (Fig 1E). However, the K403R mutant displayed negligible
response in changing acetylation and enzyme activity upon NAM
treatment (Fig 1E and Supplementary Fig S3). These results suggest
that K403 is an important regulatory acetylation site which controls
G6PD activity.
Acetylation of K403 impairs the formation of dimeric G6PD and
inhibits enzyme activity
The G6PD enzyme exists as a mixture of monomer, dimer, tetramer,
and hexamer, but only the dimeric and tetrameric forms are cata-
lytic active (Cohen & Rosemeyer, 1969; Babalola et al, 1976). The
structure of human G6PD reveals that each subunit contains two
NADP+ binding sites, a catalytic NADP+ coenzyme-binding domain
and a structural NADP+ binding domain (Au et al, 2000). The struc-
tural NADP+ binding site is distant from the catalytic site but close
to the dimer interface. The interplay of the structural NADP+ and
the dimer interface affects the stability and integrity of active
enzyme (Au et al, 2000; Wang & Engel, 2009). A high proportion of
the clinical mutations associated with severe G6PD deficiency in
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human clusters around the structural NADP+ site (Au et al, 2000;
Vulliamy & Luzzatto, 2003), suggesting that the structural NADP+
is vital for G6PD activity and function. Notably, K171 lies in the
catalysis pocket of G6PD and directly binds with both G6P and cata-
lytic NADP+, while K386 and K403 lie close to the dimer interface
(Supplementary Fig S4). In particular, K403 physically interacts with
structural NADP+ (Fig 2A). Therefore, it is possible that K171Q
mutation would abolish G6PD activity through directly influencing
the substrate recognition and/or catalysis, while K386Q and K403Q
mutations would inhibit G6PD activity through impairing the integ-
rity of dimer interface and subsequently the formation of active
dimers and higher forms of G6PD.
To test this hypothesis, we determined the interaction between
two differentially tagged G6PD proteins, G6PD-Flag and GFP-G6PD,
in HEK293T cells. We found that mutation of K171 to either R
(K171R) or Q (K171Q) did not affect the interaction between G6PD
subunits (Fig 2B). In contrast, substitution of K386Q, but not
K386R, impaired the interaction between G6PD subunits (Fig 2B).
Strikingly, substitution of K403Q, but not K403R, entirely disrupted
the interaction between G6PD subunits (Fig 2B). In addition, glutar-
aldehyde cross-linking assay demonstrated that the K403Q mutant
displayed impaired ability to form dimers when compared to wild-
type G6PD or the K403R mutant (Fig 2C). Moreover, NAM treat-
ment decreased the binding by approximately 55% between the two
differentially tagged proteins of wild-type G6PD in a dose-dependent
manner (Fig 2D and Supplementary Fig S5). NAM treatment,
however, failed to affect the interaction between Flag-tagged and
GFP-tagged K403R mutant of G6PD (Fig 2D), further suggesting that
K403 acetylation largely hinders the interaction between G6PD
subunits.
To unambiguously determine the effect of K403 acetylation on
G6PD, we employed an expression system genetically encoding
Ne-acetyllysine to prepare recombinant proteins in E. coli (Neumann
et al, 2008, 2009). This expression system produced G6PD proteins
with 100% acetylation at the targeted lysine residue. Only with
Ne-acetyllysine in the growth medium was the full-length protein
formed (Supplementary Fig S6). Moreover, we generated and veri-
fied an antibody specifically recognizing the K403 acetylated G6PD
[a-acG6PD(K403)] (Supplementary Fig S7). The incorporated acety-
llysine was confirmed by immunoblotting of the purified G6PDK403ac
protein with this site-specific a-acG6PD(K403) antibody. Impor-
tantly, as compared to wild-type and K403R/Q mutants of G6PD,
the recombinant G6PDK403ac protein displayed an identical pattern
of proteolytic cleavage after treatments with proteases, chymotryp-
sin and clostripain (Supplementary Fig S8B). Moreover, the
G6PDK403ac protein exhibited normal thermodynamic stability of
protein folding when compared to wild-type and K403R/Q mutants
of G6PD (Supplementary Fig S8C). This purified G6PDK403ac protein
was catalytic inactive (Fig 2E and Supplementary Fig S8A),
unequivocally demonstrating that acetylation of K403 inactivates
G6PD. Furthermore, our data demonstrated that the G6PDK403ac
protein was defective in dimer formation (Fig 2F). Together, these
results clearly indicate that acetylation at K403 impairs the forma-
tion of dimeric G6PD and inhibits its enzyme activity.
KAT9/ELP3 is involved in G6PD K403 acetylation and
enzymatic inactivation
Next, we set out to search for potential KAT(s) responsible for
G6PD K403 acetylation. To this end, we generated a siRNA library
with three siRNAs targeting each of the 19 human KATs (Allis et al,
2007), and then determined the activity of endogenous G6PD in
HEK293T cells with transient knockdown of individual KAT gene.
The knockdown efficiency of each siRNA was determined by quanti-
tative RT-PCR of its target gene (Fig 3A). We found that knocking
down most of the examined KAT genes did not substantially affect
the enzyme activity of endogenous G6PD (Fig 3B). With one excep-
tion, knocking down KAT9 (also known as ELP3), which encodes
the catalytic subunit of the histone acetyltransferase elongator
complex and has previously been identified as an a-tubulin acetyl-
transferase in mouse neurons (Creppe et al, 2009), significantly
stimulated the activity of endogenous G6PD (Fig 3B). Moreover, the
degree of G6PD activation appeared to correlate with the KAT9
knockdown efficiency, as siRNA no. 2 and no. 3 were more potent
in both KAT9 knockdown and G6PD activation than the siRNA no. 1.
As expected, transient knockdown of KAT9 decreased the K403
acetylation levels of endogenous G6PD without changing its protein
expression (Fig 3C and D), further supporting the notion that KAT9
is the potential acetyltransferase of G6PD.
SIRT2 activates G6PD by deacetylation
Our earlier observation that NAM increases G6PD acetylation (Fig 1A)
led us to investigate a possible involvement of NAD+-dependent
Figure 1. Acetylation negatively regulates G6PD activity.
A G6PD acetylation inhibits its enzyme activity. Flag-tagged G6PD was expressed in HEK293T cells treated with NAM or NAM+TSA at the indicated concentrations.
Acetylation levels and enzyme activity of Flag bead-purified G6PD were determined by Western blot analysis and enzyme assay, respectively. Acetylation levels
were blotted with a pan-anti-acetyllysine antibody (a-Ac). Catalytic activity of affinity-purified G6PD was determined and normalized to protein levels. G6PD
activity under no treatment condition was set as 100%. Shown are average values with standard deviation (s.d.) of triplicated experiments. IB and IP denote
immunoblotting and immunoprecipitation, respectively. ** denotes P < 0.01 for cells treated with NAM/TSA for the indicated periods versus no NAM/TSA
treatment; n.s. = not significant. G6PD acetylation levels were normalized against Flag.
B G6PD is activated by in vitro deacetylation. Affinity-purified Flag-tagged G6PD was incubated with recombinant CobB with or without NAD+ at 37°C for 2 h. G6PD
acetylation and activity were determined. Shown are average values with standard deviation (s.d.) of triplicated experiments. ** denotes P < 0.01 for cells treated
with CobB and/or NAD+ versus no treatment (NT); n.s. = not significant. G6PD acetylation levels were normalized against Flag.
C, D Mapping the major regulated sites of acetylation in G6PD. Wild-type (WT) G6PD and the indicated mutants were each expressed in HEK293T cells. Proteins were
purified by IP, and specific G6PD activity was determined. Shown are average values with standard deviation (s.d.) of triplicated experiments. ** denotes P < 0.01
for cells expressing the indicated G6PD mutants versus cells expressing WT G6PD; n.s. = not significant.
E K403 is the important regulatory acetylation site in G6PD. Flag-tagged wild-type G6PD, the K171R, K386R, and K403R mutants were each expressed in HEK293T
cells, followed by treatments with or without 15 mM NAM. Acetylation levels and activity of G6PD were determined. Shown are average values with standard
deviation (s.d.) of triplicated experiments. ** denotes P < 0.01 for the indicated comparison; n.s. = not significant. G6PD acetylation levels were normalized against
Flag.
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Figure 3. KAT9/ELP3 is the potential acetyltransferase of G6PD.
A A siRNA library with three siRNAs targeting each of the 19 known HAT genes was generated. Each siRNA oligonucleotide was transiently transfected into HEK293T
cells, and mRNA expression of HAT genes was determined by quantitative real-time PCR at 48 h post-transfection.
B HEK293T cells were transfected as described in (A) and then were subjected to G6PD activity assay.
C, D Three different siRNAs targeting KAT9 were transiently transfected into HEK293T cells. Protein expression and enzyme activity (C) and the K403 acetylation level (D)
of endogenous G6PD were determined. Shown are average values with standard deviation (s.d.) of triplicated experiments. ** denotes P < 0.01 for the indicated
comparison; n.s. = not significant.
Figure 2. K403 acetylation impairs the formation of dimeric G6PD and inhibits its enzyme activity.
A Cartoon representation of G6PD structure (PDB ID: 2BH9) (Kotaka et al, 2005) made by using Pymol (www.pymol.org). Upper left, electrostatic (G6PD) and stick
(NADP+) representation of the crystal structure of G6PD bound to NADP+. Upper right, a closer view showing the structural NADP+ bound to a positive charged
groove of G6PD. Lower panel, shown is a ribbon (G6PD)-and-stick (structural NADP+) representation of G6PD bound to the structural NADP+. The protein is colored
in light green and NADP+ in yellow, with interacting residues on G6PD colored in magenta. Arrow indicates the interaction between Lys 403 and the structural
NADP+.
B Acetylation at K403 blocks the protein-protein binding between wild-type G6PD. Flag-tagged G6PD, KR/KQ mutants of K171, K386, and K403 were each expressed in
HEK293T cells co-expressing GFP-tagged G6PD. The interaction between Flag-tagged and GFP-tagged proteins was determined by Western blotting.
C K403Q mutation, but not K403R, inhibits the formation of dimeric G6PD. Flag-tagged G6PD, G6PDK403R, and G6PDK403Q were each expressed in HEK293T cells,
followed by treatments with or without 0.025% glutaraldehyde. The formation of G6PD monomer and dimer was determined by Western blotting.
D NAM treatment impairs the protein-protein interaction between WT G6PD, but not the K403R mutant. Flag-tagged G6PD and G6PDK403R were each expressed in
HEK293T cells co-expressing GFP-tagged G6PD and G6PDK403R, respectively. Cells were treated with or without 15 mM NAM, and the interaction between Flag-
tagged and GFP-tagged proteins was determined by Western blotting.
E, F In vitro site-specific incorporation of acetylated K403 in G6PD. His-tagged G6PD and G6PDK403ac were recombinantly expressed and detected by Western blot with
an anti-His antibody as well as a site-specific anti-acetyllysine antibody [a-acG6PD(K403)]. G6PD activity assay was performed using the purified unacetylated
G6PD and G6PDK403ac proteins (E). Moreover, the purified unacetylated G6PD and G6PDK403ac proteins were treated with or without 0.025% glutaraldehyde, and the
formation of G6PD monomer and dimer was tested by Western blotting (F). Purified Flag-tagged G6PDK403Q was used as a control. ** denotes P < 0.01 for the
purified G6PDK403ac protein versus the unacetylated G6PD protein.
◂
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sirtuins in G6PD deacetylation. The first known sirtuin, Sir2 (silent
information regulator 2) of Saccharomyces cerevisiae (Imai et al,
2000), from which the family derives its name, regulates lifespan in
worms and flies (Michan & Sinclair, 2007). Mammals contain seven
Sir2 homologues, SIRT1-7, each with diverse subcellular localization
and protein substrates. SIRT1-3 display robust deacetylation activ-
ity, while SIRT4-7 have no detectable or very weak deacetylase
activity and show diverse substrate specificity (Hirschey, 2011;
Feldman et al, 2013). Given that G6PD is localized in the cytoplasm
(Notaro et al, 2000), we examined whether cytosolic SIRTs, SIRT1
or SIRT2 (Michishita et al, 2005; Schwer & Verdin, 2008), could
deacetylate G6PD and stimulate its enzymatic activity. We observed
that G6PD directly interacted with SIRT2, but not SIRT1 (Fig 4A and
B). Co-expression of SIRT2 with G6PD in HEK293T cells decreased
the acetylation level of G6PD by 50%, while increased G6PD
enzyme activity by twofold (Fig 4C). When G6PD was co-expressed
with a catalytic inactive mutant of SIRT2, SIRT2H187Y (North et al,
2003), neither G6PD acetylation nor enzyme activity was changed
(Fig 4C), connecting G6PD deacetylation and activation directly to
SIRT2 catalytic activity. Furthermore, we found that SIRT2 deacety-
lated and activated wild-type G6PD and the K386R mutant, but not
the K403R mutant (Fig 4D), confirming that K403 is an important
site of acetylation in the regulation of G6PD activity by SIRT2.
Co-expression of SIRT2, but not the catalytic inactive SIRT2H187Y
mutant, increased the interaction between two differentially tagged
G6PD, and this effect could be diminished by NAM treatment
(Fig 4E). In addition, AGK2, a SIRT2-specific inhibitor (Outeiro
et al, 2007), inhibited the dimer formation of wild-type G6PD,
while the K403R mutant displayed negligible response in the
monomer-to-dimer transition upon AGK2 treatment (Fig 4F). Taken
together, these findings demonstrate that SIRT2 stimulates G6PD
activity by deacetylating G6PD at K403 to stimulate the formation
of active dimers.
K403 acetylation plays a signaling role in regulating G6PD
enzyme activity under oxidative stress
Being the key enzyme that controls the PPP, G6PD activity is tightly
regulated by the [NADPH/NADP+] ratio in the cell. G6PD is inhib-
ited by the high steady-state ratio of [NADPH] to [NADP+] in cells
under non-stress conditions (Berg et al, 2006), while G6PD and the
pentose phosphate pathway activity are stimulated to restore
NADPH after exposure to extracellular oxidants (Cramer et al, 1995;
Slekar et al, 1996; Ursini et al, 1997; Filosa et al, 2003), which are
supposed to decrease the intracellular NADPH level (Xu et al, 2010).
To determine whether acetylation at K403 is involved in the regula-
tion of G6PD activity during oxidative stress, we treated HEK293T
cells ectopically expressing wild-type G6PD or the K403R mutant
with agents that directly induce oxidative stress, including hydrogen
peroxide (H2O2) and menadione (a quinone compound that induces
the production of superoxide radicals). We found that treatment with
H2O2 (300 lM) led to a rapid (within 15-min) decrease in the K403
acetylation level of wild-type G6PD and thereby rapidly increased
G6PD activity (Supplementary Fig S9A). In contrast, the cells
expressing K403R mutant displayed a negligible response in chang-
ing enzyme activity in response to H2O2. Similar changes in G6PD
K403 acetylation and enzyme activity were found in cells expressing
wild-type G6PD upon treatment with menadione (50 lM), and again,
the K403R-expressing cells displayed a negligible response in chang-
ing enzyme activity in response to menadione (Fig 5A).
To accurately measure intracellular redox status, we established
HEK293 cells stably expressing cytosolic redox-sensitive green fluo-
rescent protein 1 (HEK293roGFP1) which allows real-time visualiza-
tion of thiol-disulfide metabolic state in the cytosol of living cells
(Dooley et al, 2004). We found that the disulfide level in H2O2-
exposed cultures peaked at 10 min and was followed by a rapid full
recovery (Supplementary Fig S9B). Notably, the K403 acetylation
level of endogenous G6PD was rapidly (within 15 min) decreased in
response to H2O2 followed by a period of recovery that slowly lagged
after the recovery of cellular disulfide level (Supplementary Fig S9B).
When cells were treated with menadione, the disulfide level was
steadily increased, and a recovery occurred only after menadione
was washed out from the culture (Fig 5B). G6PD K403 acetylation
also showed an inverse, but delayed correlation with the oxidized
disulfide. To more accurately quantify these changes in endogenous
G6PD K403 acetylation, we used the recombinant G6PDK403ac protein
purified from E. coli as the standard and found that approximately
34% of endogenous G6PD was acetylated at K403 in HEK239T cells,
which was decreased to approximately 9% after menadione treat-
ment (Fig 5C). These results indicate that G6PD K403 acetylation is
regulated by cellular oxidative status and likely plays a signaling role
in the dynamic regulation of G6PD activity.
To evaluate the function of G6PD K403 acetylation in regulating
cellular NADPH homeostasis, we generated stable G6PD-knockdown
Figure 4. SIRT2 decreases G6PD acetylation and increases its enzyme activity by inducing the formation of dimeric G6PD.
A, B G6PD interacts with SIRT2, but not SIRT1. Flag-tagged G6PD was expressed in HEK293T cells together with the individual HA-tagged SIRT as indicated. Proteins
were purified by IP with Flag beads, followed by Western blot to detect SIRTs with a HA antibody (A). On the other hand, SIRT1 and SIRT2 proteins were purified by
IP with HA beads, followed by Western blot to detect G6PD with a Flag antibody (B).
C G6PD is deacetylated and activated by SIRT2, but not SIRT1. Flag-tagged G6PD was expressed in HEK293T cells together with the individual HA-tagged SIRT as
indicated. Among them, SIRT2H187Y is a catalytically inactive mutant. G6PD proteins were purified by Flag beads, and acetylation levels and enzyme activity were
determined by Western blot analysis and enzyme assay, respectively. Shown are average values with standard deviation (s.d.) of triplicated experiments. G6PD
acetylation levels were normalized against Flag protein levels.
D SIRT2 deacetylates G6PD mainly at the site of K403. Flag-tagged G6PD, G6PDK386R, and G6PDK403R were each expressed in HEK293T cells co-expressing HA-tagged
SIRT2. G6PD proteins were purified by Flag beads, and acetylation levels were determined by Western blot. Shown are average values with standard deviation (s.d.)
of triplicated experiments. ** denotes P < 0.01 for the indicated comparison; n.s. = not significant.
E SIRT2 increases the protein-protein interaction between wild-type G6PD. GFP-tagged and Flag-tagged G6PD were co-transfected along with HA-tagged SIRT2 or its
catalytic inactive mutant SIRT2H187Y in HEK293T cells. Cells were treated with or without 15 mM NAM, and the interaction between Flag-tagged and GFP-tagged
proteins was determined by Western blotting. GFP protein levels were normalized against Flag protein levels.
F Inhibition of SIRT2 decreases the formation of dimeric G6PD. G6PD and G6PDK403R were each expressed in HEK293T cells, followed by treatments without or with
AGK2 (10 lM). Extracts of the cells were treated with or without 0.025% glutaraldehyde, and the formation of G6PD monomer and dimer was determined by
Western blotting.
▸
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and G6PD-rescued cells in HEK293T (Supplementary Fig S10).
HEK293T cells with G6PD-knockdown displayed an approximately
45% reduction in the [NADPH]/[NADP+] ratio, reaffirming that
G6PD is an important contributor to NADPH pools in the cell
(Fig 5D). The lower [NADPH]/[NADP+] ratio was in accord with
the higher ROS production in G6PD-knockdown cells subjected to
menadione (Fig 5E). Importantly, re-expression of wild-type G6PD,
but not the acetylated mimetic K403Q mutant, restored the
[NADPH]/[NADP+] ratio and suppressed ROS production in G6PD-
knockdown and rescue cells subjected to menadione (Fig 5D and E).
ROS has been extensively implicated in signaling cascades which
function as important cell survival mechanisms in response to
oxidative stress (Kregel & Zhang, 2007). As compared to control
cells expressing an empty vector, when treated with menadione
G6PD-knockdown cells exhibited higher levels of cleaved PARP and
Caspase-3, two indicators of apoptosis (Supplementary Fig S11A),
as well as higher levels of p38 MAPK phosphorylation, a stress
responsive kinase (Supplementary Fig S11B). Re-introduction of
wild-type G6PD, but not the acetylated mimetic K403Q mutant,
reduced the levels of cleaved PARP and Caspase-3, and p38 MAPK
phosphorylation in G6PD-knockdown cells when subjected to mena-
dione (Supplementary Fig S11). Consequently, G6PD-knockdown
cells exhibited a higher incidence of cell death in response to mena-
dione, and re-expression of wild-type G6PD, but not the acetylated
mimic K403Q mutant, could rescue cells from menadione-induced
cell death (Fig 5F). These findings clearly support an important role
of G6PD K403 acetylation in controlling NADPH production and
protecting cells from oxidative stress.
SIRT2 controls G6PD K403 deacetylation in response to
oxidative stress
G6PD-knockdown cells were highly sensitive to menadione in both
ROS production and cell death (Fig 6A and B). Inhibition of SIRT2
by AGK2 did enhance the effect of menadione on ROS production
and cell death in both the control and wild-type G6PD-rescued cells
(Fig 6A and B). Notably, AGK2 was unable to enhance the effect
of menadione on ROS production and cell death in the G6PD-
knockdown or K403R/K403Q-rescued cells, indicating that G6PD is
required for AGK2 to synergize with menadione. Supporting this
concept, transient knocking down SIRT2, but not SIRT1, increased
the K403 acetylation level of endogenous G6PD in HEK293T cells
(Supplementary Fig S12A and B), and SIRT2 knockdown enhanced
the effect of menadione on ROS production and cell death in both
the control and G6PD-rescued cells, but not in the G6PD-knockdown
or K403R/K403Q-rescued cells (Supplementary Fig S12C).
Interestingly, we found that either H2O2 or menadione did not
change the transcriptional expression of SIRT2 gene (Supplementary
Fig S13A and B), but significantly activated the deacetylase activity
of SIRT2 (Fig 6C). In vitro incubation of SIRT2 protein with redox
reagents, such as either H2O2 or dithiothreitol (DTT), did not affect
the deacetylase activity of SIRT2, suggesting that the observed enzy-
matic activation of SIRT2 by oxidants is not caused by the formation
of disulfide bonds (Supplementary Fig S13C). On the other hand,
the protein interaction between endogenous SIRT2 and G6PD was
weak in cells under a non-stress condition, and this interaction was
profoundly enhanced by treatment with either H2O2 or menadione
(Fig 6D). As a result, the K403 acetylation level of endogenous
G6PD was decreased by > 50% by these extracellular oxidants
(Fig 6E and F), and such decreases were completely blocked by
AGK2 treatment (Fig 6E and F).
Taken together, our data indicate that K403 acetylation is crucial
for the function of G6PD in maintaining cellular NADPH homeo-
stasis and that oxidative stimuli affect G6PD K403 acetylation and
activity in a SIRT2-dependent manner.
G6PD K403 deacetylation and enzyme activation are protective
against oxidative stress in vivo
G6PD is particularly important for erythrocyte function and its defi-
ciency leads to hemolytic anemia (Vulliamy et al, 1993). We thus
investigated the functional importance of G6PD K403 acetylation in
erythrocytes. We found that menadione treatment did not change
the protein expression of G6pd or Sirt2 in mouse erythrocytes
◂ Figure 5. G6PD K403 deacetylation leads to G6PD activation in cells under oxidative stress.A Menadione decreases G6PD K403 acetylation and activates enzyme activity of ectopically expressed G6PD. Flag-tagged WT G6PD or the K403R mutant was expressed
in HEK293T cells and was then treated with 50 lM menadione for the indicated periods. The K403 acetylation levels and enzyme activity of Flag bead-purified G6PD
were determined by Western blot analysis and enzyme assay, respectively. Shown are average values with standard deviation (s.d.) of triplicated experiments.
** denotes P < 0.01 for cells treated with H2O2 or menadione versus cells without oxidant treatment.
B Menadione dynamically changes the K403 acetylation level of endogenous G6PD. HEK293roGFP1 cells were treated with 25 lM menadione for the indicated periods.
The relative disulfide level in the cytoplasm was monitored by using a fluorescent biosensor as described in Materials and Methods. The K403 acetylation level of
endogenous G6PD was determined by Western blot analysis. Shown are average values with standard deviation (s.d.) of triplicated experiments. Relative G6PD K403
acetylation levels were normalized against G6PD protein levels.
C Determination of endogenous G6PD K403 acetylation ratio. Recombinant fully K403 acetylated G6PD was loaded onto the same gel with endogenous G6PD from
HEK293T cells treated with or without 50 lM menadione for 30 min. G6PD protein and K403 acetylation were detected by Western blot. Relative K403 acetylation
ratios were calculated after normalizing against G6PD protein levels.
D K403 is critical for G6PD function to produce NADPH. The ratio of reduced and oxidized forms of NADP, that is the ratio of [NADPH to NADP+], was determined by the
enzymatic analysis of cell extracts from G6PD-knockdown cells re-expressing the indicated proteins after treatments with or without menadione (50 lM for 30 min).
Shown are average values with standard deviation (s.d.) of triplicated experiments. ** denotes P < 0.01 for the indicated comparison; n.s. = not significant.
E K403 is critical for G6PD function to suppress cellular ROS production under oxidative stress. G6PD-knockdown cells or these cells rescued by WT G6PD or the K403Q
mutant were treated with menadione (50 lM for 30 min), and ROS accumulation was determined by using a fluorescent dye as described in Supplementary
Materials and Methods. Shown are average values with standard deviation (s.d.) of triplicated experiments. * denotes P < 0.05, and ** denotes P < 0.01 for the
indicated comparison; n.s. = not significant.
F K403 is critical for G6PD function to protect cells from ROS-induced cell death. G6PD-knockdown cells and these cells rescued by WT G6PD or the K403Q mutant were
treated with the indicated concentrations of menadione for 3 h, and cell viability was determined by counting the remaining adherent cells. Shown are average
values with standard deviation (s.d.) of triplicated experiments. ** denotes P < 0.01 for knockdown and rescue cells versus knockdown cells; n.s. = not significant.
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Figure 6. SIRT2 controls G6PD K403 acetylation in response to oxidative stress.
A, B Inhibition of SIRT2 increases cellular susceptibility to oxidative stress. G6PD-knockdown and G6PD-rescued cells were treated with AGK2 (10 lM) for 4 h alone and/
or menadione (50 lM) for 30 min. ROS accumulation was determined by using a fluorescent dye as described in Supplementary Materials and Methods (A), and
cell viability was determined by counting the remaining adherent cells (B). Shown are average values with standard deviation (s.d.) of triplicated experiments.
* denotes P < 0.05, and ** denotes P < 0.01 for the indicated comparison; n.s. = not significant.
C Chemical oxidants activate the deacetylase activity of SIRT2. HA-tagged SIRT2 or its catalytic inactive mutant (H187Y) was ectopically expressed in HEK293T cells
and then treated with menadione (50 lM) or H2O2 (300 lM) for the indicated periods. HA-SIRT2 was purified by IP with HA beads, eluted with HA peptide, and
subjected to deacetylase activity assay. Shown are average values with standard deviation (s.d.) of triplicated experiments. * denotes P < 0.05, and ** denotes
P < 0.01 for cells treated with menadione or H2O2 versus cells without oxidant treatment.
D Chemical oxidants enhance the interaction between endogenous G6PD and SIRT2. HEK293T cells were treated with menadione (50 lM) or H2O2 (300 lM) for
30 min. The association of endogenous G6PD with SIRT2 was determined by Western blotting.
E, F Inhibition of SIRT2 blocks the effect of chemical oxidants on changing G6PD K403 acetylation. HEK293T cells were treated with or without 10 lM AGK2 for 4 h
before treatment with menadione (50 lM) (E) or H2O2 (300 lM) (F) for 30 min, and the K403 acetylation level of endogenous G6PD was determined by Western
blot analysis. Relative K403 acetylation ratios were calculated after normalizing against G6PD protein levels.
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(Supplementary Fig S14), but did decrease the K403 acetylation
level of G6pd by fourfold and consequently increased G6pd activity
by 1.8-fold (Fig 7A). These alterations in G6pd K403 acetylation and
activity were, however, prevented by the addition of AGK2. As a
result, combined exposure to AGK2 and menadione had synergistic
effects on inducing ROS production and cell death in mouse erythro-
cytes (Fig 7A). Additionally, Sirt2 deletion led to higher levels of
menadione-induced ROS in erythrocytes from both female and male
mice (Fig 7B), further supporting a role of SIRT2 in G6PD regula-
tion. Moreover, we found that Sirt2 deletion led to higher levels of
G6pd K403 acetylation in mouse erythrocytes (Fig 7C). After mena-
dione treatment, erythrocytes from wild-type mice exhibited a
dramatic reduction in G6pd K403 acetylation level, while those from
Sirt2-deficient animals displayed negligible response in changing
G6pd K403 acetylation (Fig 7C).
Finally, we examined the effects in mouse embryonic fibroblasts
and again found that menadione treatment remarkably decreased
K403 acetylation and increased activity of G6pd (Fig 7D). To deter-
mine the function of Sirt2, Sirt2-null MEFs were tested (Supplemen-
tary Fig S15A). In these cells, Sirt2 deletion led to a higher level of
K403 acetylation and impaired activity of G6pd when compared to
wild-type MEFs under a non-stress condition (Fig 7D). After mena-
dione treatment, significant cell death was observed in Sirt2-null
MEFs as compared to wild-type cells (Fig 7D and Supplementary Fig
S15B). It has to be noted that menadione treatment did not change
the K403 acetylation level of G6pd in Sirt2-null MEFs, but did acti-
vate G6pd enzyme in these cells though less dramatic than the
control cells (Fig 7D), implying that G6PD could also be regulated
by additional mechanisms besides the deacetylation by SIRT2.
Nevertheless, stable expression of a human version SIRT2 in Sirt2-
null MEF cells reduced the K403 acetylation of G6pd and sustainably
activated G6pd to counterbalance menadione-induced ROS stress
(Fig 7D). As a result, human SIRT2 rescued Sirt2-null MEF cells
from menadione-induced cell death (Fig 7D), confirming the role of
SIRT2 in G6PD activation and ROS scavenging.
Discussion
The current study uncovers a biochemical mechanism about
how acetylation controls the activity/function of G6PD to
modulate cellular NADPH homeostasis. SIRT2 plays a key role
in G6PD deacetylation and activation, which is critical to
maintain cellular redox potential and protects cells from oxidative
damage.
We have identified K403 as an important regulatory acetylation
site within the G6PD protein, which is supported by Western blot-
ting of a K403 acetylation-specific antibody. K403 is located near the
dimer interface and interacts with the structural NADP+, which is
believed to be critical for the stability and integrity of the active
form of G6PD (Wang et al, 2006; Wang & Engel, 2009). Our data
show that K403Q substitution (acetylated mimic) displays a signifi-
cant reduction in G6PD catalysis and is defective in dimer forma-
tion. This model is further supported by the recombinant
G6PDK403ac protein, which is also inactive and fails to form dimers.
Based on these findings, we hypothesize that acetylation at K403 of
G6PD, partially through the ablation of the positively charged bind-
ing pocket at the dimer interface, may prevent the proper binding of
the structural NADP+, thus leading to decreased dimer formation
and enzyme activity.
Our study provides insights into the role of K403 acetylation in
coordinating the monomer-to-dimer transition of G6PD in response
to oxidative stress. It also raises a question regarding how cells
sense physiologic stimuli to regulate G6PD acetylation. The NAD+
requirement of SIRTs for deacetylation suggests that these proteins
may be sensors of the energy or redox state of cells. Increasing
evidence indicates that SIRT2 is implicated in metabolism regulation
and possibly cellular energy response (Cen et al, 2011; Guarente,
2011; Jiang et al, 2011b; Satoh et al, 2011). Other reports in yeast
and mice under caloric-restricted conditions suggest that SIRT2 may
also play a role in helping cells to cope with oxidative stress
(Lamming et al, 2005; Wang et al, 2007; Zhu et al, 2012). To date,
many substrates of SIRT2 have been identified, including a-tubulin
(North et al, 2003), histone H3/H4 (Vaquero et al, 2006; Das et al,
2009), FOXO3A (forkhead box O transcription factor 3a) (Wang
et al, 2007), and PEPCK1 (phosphoenolpyruvate carboxykinase 1)
(Jiang et al, 2011b). Among them, only FOXO3A can be indirectly
linked to ROS scavenging: SIRT2-dependent deacetylation of
FOXO3A stimulates the expression of FOXO-targeting genes, thereby
reducing cellular ROS and decreasing cell death (Wang et al, 2007).
In this study, we show for the first time that G6PD is a direct
substrate of SIRT2. Our data demonstrate that oxidative stimuli
enhance the SIRT2-G6PD protein interaction and meanwhile increase
the deacetylation activity of SIRT2, thereby helping cells to sense
oxidative stress and maintain NADPH homeostasis through regulating
G6PD K403 acetylation in a SIRT2-dependent manner. The observed
enzymatic activation of SIRT2 by oxidants is apparently not attributed
to the formation of disulfide bonds within the SIRT2 protein, and the
underlying mechanism still requires further investigation.
In unstressed cells, PPP is greatly inhibited while glycolysis is the
major carbon metabolic pathway. When cells get in contact with an
oxidant, the glycolysis pathway is blocked, driving glucose flux into
the PPP (Gruning et al, 2011). Both aspects need prompt change of
cellular G6PD activity since it is the first rate-limiting enzyme in
PPP. Our present study reveals that SIRT2-mediated K403 deacetyla-
tion and subsequent activation of G6PD rapidly (within 15 min)
stimulates PPP to supply intracellular reductant in the form of
NADPH to counteract oxidative damage. Interestingly, once extra-
cellular oxidative stress is removed, G6PD K403 acetylation can be
normalized to basal levels, leading to G6PD inhibition and PPP re-
suppression. Our study reveals an intriguing mechanism that oxida-
tive status dynamically regulates G6PD activity via SIRT2 to control
cellular NADPH homeostasis and redox balance (Fig 7E). Compared
with a transcription-based mechanism that usually takes hours, a
post-translational modification of G6PD by acetylation can occur
much more quickly and thus could serve as a better way for acute
anti-oxidative response in cell protection.
The clinical implication of human G6PD deficiency has been
mostly focused on the associated hemolysis or on the relationship to
protection from malaria (Ding et al, 2013). In addition, limited studies
indicate that the incidence of cancer and coronary artery disease is
inversely related to the frequency of G6PD deficiency (Beaconsfield
et al, 1965; Long et al, 1967; Cocco et al, 1998; Meloni et al, 2008;
Manganelli et al, 2013). Higher expression level of G6PD is associ-
ated with breast cancer metastasis and is thought to contribute to
tumor cell proliferation by enhanced ribose and NADPH supply
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(Jiang et al, 2011a; Du et al, 2013). Moreover, G6PD deficiency,
perhaps through decreasing the NADPH-dependent cholesterol
synthesis, may be advantageous against the risk of heart disease in
both G6PD-deficient mouse models and clinical studies (Matsui
et al, 2006; Muntoni, 2008; Rawat et al, 2012). Furthermore,
decreased G6PD activity may predispose to the occurrence of diabe-
tes and aldosterone-induced endothelial dysfunction (Leopold et al,
2007; Zhang et al, 2010). Supporting this notion, highly significant
decreases in G6PD activity due to hyperglycemia or diabetes were
observed in various cultured cells and animal tissues (Zhang et al,
2000; Xu et al, 2005). Additionally, G6PD-deficient subjects were
reported to show a higher frequency of diabetes mellitus when
compared with subjects from the same population who have
wild-type G6PD activity (Saeed et al, 1985; Niazi, 1991). Another
example for the pathophysiological role of G6PD comes from the
finding that aldosterone induces a G6pd-deficient phenotype to
impair endothelial function, while aldosterone antagonism or gene
transfer of G6pd improves vascular reactivity by restoring G6pd
activity (Leopold et al, 2007). Therefore, the role of G6PD deficiency
in the pathophysiology of various diseases may be context depen-
dent. In the present study, we have provided comprehensive evidence
showing that SIRT2 plays a key role in mediating G6PD deacetyla-
tion and activation, which is critical for cells to sense physiological
oxidative stress and maintain cellular redox potential to protect against
oxidative damage. Therefore, future therapeutic intervention(s) to
modulate G6PD activity via SIRT2-mediated deacetylation may serve
as a potential target for treating the related disease.
Materials and Methods
G6PD enzyme activity assay
G6PD enzyme activity was determined as described previously (Tian
et al, 1998). To obtain endogenous G6PD activity, both PGD activity
alone and total dehydrogenase activity (G6PD + PGD) were
measured separately. G6PD activity was calculated by subtracting
the activity of PGD from total enzyme activity. Reaction mixture
consists of 50 mM Tris–HCl (pH 7.6), 0.1 mM NADP+, 0.2 mM
glucose-6-phosphate (G6P), or 0.2 mM 6-phosphogluconate in a
total volume of 300 ll. Reactions were initiated by adding enzyme
and analyzed at 25°C. Activities were measured by the conversion of
NADP+ to NADPH, which was monitored by measuring the increase
in fluorescence (Ex. 350 nm, Em. 470 nm, HITACH F-4600 fluores-
cence spectrophotometer) for NADPH generation. Flag-tagged G6PD
proteins were expressed in HEK293T cells, immunoprecipitated with
Flag beads, eluted by Flag peptides (Gilson Biochemical), and
subjected into activity assay with G6P and NADP+ as substrates.
Expression of the K403 site-specific acetylated G6PD
The K403 site-specific acetylated G6PD was expressed in E. coli
as previously described (Neumann et al, 2008). In short, the
Escherichia coli strain BL21 (DE3) was transformed with plasmids,
pAcKRS-3 and pCDF PylT-1 carrying the ORF for G6PD with amber
codon at the K403 site. Cells were grown overnight in LB containing
50 lg/ml kanamycin and 50 lg/ml spectinomycin (LB-KS) at 37°C
till OD600 reached 0.6–0.8, and the culture was added with 20 mM
NAM and 10 mM acetyllysine (AcK, Sigma). Protein expression was
induced at 37°C 30 min later by the addition of 0.5 mM of
isopropyl-1-thio-D-galactopyranoside (IPTG). Afterward, incubation
was continued at 37°C for 3 h, and the cells were harvested, washed
with PBS containing 20 mM NAM, and then stored at 80°C till
further analysis.
Generation of stable G6PD-knockdown cell pools
To generate stable G6PD-knockdown cell pools in HEK293T cells,
shRNA targeting G6PD was constructed, and retrovirus was
produced using a two-plasmid packaging system as previously
described (Christofk et al, 2008). The shRNA targeting sequence for
G6PD is 50-GGCCGTCACCAAGAACATTCA-30. The shRNA construct
was co-transfected with vectors expressing the gag and vsvg genes
into HEK293T cells. Retroviral supernatant was harvested 36 h after
transfection and mixed with 8 lg/ml polybrene to increase the
infection efficiency. Cells were infected with the retrovirus and
selected in 1 lg/ml puromycin for 1 week.
Real-time monitoring of the disulfide formation
Redox-sensitive green fluorescent proteins (roGFPs) allow real-time
visualization of the oxidation state of the indicator (Dooley et al,
Figure 7. G6PD K403 deacetylation and activation are protective against oxidative stress in vivo.
A Inhibition of SIRT2 impairs ROS scavenging in mouse erythrocytes. Mouse erythrocytes were freshly isolated and treated with AGK2 (10 lM) for 4 h alone and/or
menadione (50 lM) for 30 min, and the K403 acetylation level of endogenous G6PD was determined by Western blot analysis. In addition, endogenous G6PD
activity and cellular ROS accumulation were determined as described in Supplementary Materials and Methods. Moreover, mouse erythrocytes were treated with
increasing concentrations of menadione as indicated along with or without 10 lM AGK2 for 6 h. Cell death assay was performed by counting floating trypan blue-
positive cells. Shown are average values with standard deviation (s.d.) of triplicated experiments. * denotes P < 0.05, and ** denotes P < 0.01 for comparing cells
after the indicated treatment; n.s. =not significant. Relative G6pd K403 acetylation levels were normalized against G6pd protein levels.
B, C Deletion of Sirt2 impairs ROS scavenging in mouse erythrocytes. Erythrocytes from wild-type or Sirt2-knockout mice (male n = 3 and female n = 3 per group) were
isolated and treated with menadione (50 lM for 30 min). Cellular ROS accumulation was determined as described in Supplementary Materials and Methods (B)
and the K403 acetylation level of endogenous G6pd was determined by Western blot analysis (C). Lysate of wild-type male mouse no. 1 was used as a loading
control (con) for different panels. ** denotes P < 0.01 for the indicated comparisons; n.s. = not significant.
D Deletion of Sirt2 impairs ROS scavenging in mouse MEF cells. Wild-type, Sirt2-depleted, and Sirt2-depleted and rescued MEF cells were treated with menadione
(50 lM) for 30 min. The K403 acetylation level of endogenous G6PD was determined by Western blot analysis. In addition, endogenous G6PD activity and cellular
ROS accumulation were determined as described in Supplementary Materials and Methods. Moreover, mouse MEF cells were treated with increasing
concentrations of menadione as indicated for 3 h. Cell survival was assessed by counting adherent MEF cells. Shown are average values with standard deviation
(s.d.) of triplicated experiments. * denotes P < 0.05, and ** denotes P < 0.01 for comparing cells after the indicated treatment; n.s. = not significant. Relative G6PD
K403 acetylation levels were normalized against G6PD protein levels.
E A working model for G6PD K403 acetylation plays a key role in regulating cellular NADPH homeostasis and redox balance under oxidative stress.
◂
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2004). The thiol-disulfide metabolic state was monitored in HEK293
cells stably expressing roGFP1 in the cytosol (HEK293roGFP1). Cells
were harvested by trypsinization, washed, and resuspended in PBS
containing 25 mM glucose. The aliquots of cells were incubated at
37°C with 150 lM H2O2 or 50 lM menadione. Menadione was
removed from the culture at 30 min post-treatment by centrifuging
cells at 100 g for 5 min and washed twice and resuspended in PBS
containing 25 mM glucose. The disulfide formation potential was
measured by a Spectra Max M5 microplate Reader (Molecular
Devices) and calculated by determining the excitation ratio (400/
485 nm). Fluorescence values were background-corrected by
subtracting the intensity of HEK293 cell samples not expressing
roGFP1. All the samples were run in triplicate.
Statistical analyses
Statistical analyses were performed with a two-tailed unpaired
Student’s t-test. All data shown represent the results obtained from
triplicated independent experiments with standard errors of the
mean (mean  s.d.). The values of P < 0.05 were considered statis-
tically significant.
Supplementary information for this article is available online:
http://emboj.embopress.org
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